On August 26, 2010, Huang, Adrian; Moretto, Alessandro; Janz, Kristin; Lowe, Michael; Bedard, Patricia W.; Tam, Steve; Di, Li; Clerin, Valerie; Sushkova, Natalia; Tchernychev, Boris; Tsao, Desiree H. H.; Keith, James C. Jr.; Shaw, Gray D.; Schaub, Robert G.; Wang, Qin; Kaila, Neelu published an article.Application of 141940-37-6 The title of the article was Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury. And the article contained the following:
Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclin. development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Application of 141940-37-6
The Article related to quinoline preparation p selectin inhibitor sar, Pharmacology: Structure-Activity and other aspects.Application of 141940-37-6
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics